MDI 403

Drug Profile

MDI 403

Latest Information Update: 26 Aug 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Design International
  • Class Antiacnes; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Photodamage

Most Recent Events

  • 24 Aug 2004 Molecular Design International is now pursuing development of MDI 403 as a cosmetic product for fine line wrinkle reduction
  • 24 Aug 2004 Discontinued - Phase-I for Photodamage in USA (Topical)
  • 24 Aug 2004 Discontinued - Phase-II for Acne in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top